Ad
related to: hgpin prognosis calculator based on gender and child mortality datawhattoexpect.com has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
High-grade prostatic intraepithelial neoplasia (HGPIN) is an abnormality of prostatic glands and believed to precede the development of prostate adenocarcinoma (the most common form of prostate cancer). [1] [2] It may be referred to simply as prostatic intraepithelial neoplasia (PIN).
Sex gap in life expectancy and healthy life expectancy [1]. The male-female health survival paradox, also known as the morbidity-mortality paradox or gender paradox, is the phenomenon in which female humans experience more medical conditions and disability during their lives, but live longer than males.
The infant mortality rate is the number of deaths of infants under one year old per 1,000 live births. This rate is often used as an indicator of the level of health in a country. The child mortality rate is the number of deaths of infants and children under five years old per 100,000 live births.
Survival rate is a part of survival analysis.It is the proportion of people in a study or treatment group still alive at a given period of time after diagnosis. It is a method of describing prognosis in certain disease conditions, and can be used for the assessment of standards of therapy.
The risk adjusted mortality rate (RAMR) is a mortality rate that is adjusted for predicted risk of death. It is usually utilized to observe and/or compare the performance of certain institution(s) or person(s), e.g., hospitals or surgeons. It can be found as: RAMR = (Observed Mortality Rate/Predicted Mortality Rate)* Overall (Weighted ...
MDCalc is a free online medical reference for healthcare professionals that provides point-of-care clinical decision-support tools, including medical calculators, scoring systems, and algorithms. [1]
Five-year survival rates can be used to compare the effectiveness of treatments. Use of five-year survival statistics is more useful in aggressive diseases that have a shorter life expectancy following diagnosis, such as lung cancer, and less useful in cases with a long life expectancy, such as prostate cancer.
The index was developed by Mary Charlson and colleagues in 1987, but the methodology has been adapted several times since then based on the findings of additional studies. [5] Many variations of the Charlson comorbidity index have been presented, including the Charlson/Deyo, Charlson/Romano, Charlson/Manitoba, and Charlson/D'Hoores comorbidity ...